SNPS vs ARM vs VLN Stock Comparison

Synopsys, Arm Holdings and Valens Semiconductor Prices as of Oct 26, 2026 Peers: Industry group
SNPS Synopsys Inc
$454.33 +6.7% 1M -2.1% 1Y
Market cap
$90.76B
P/E
69.7x
Revenue (TTM)
$8.88B
Div. yield
–
Semiconductor EDA Software Technology
7 wins
ARM Arm Holdings Plc /Uk
$223.35 -28.0% 1M +30.9% 1Y
Market cap
$239.36B
P/E
229.3x
Revenue (TTM)
$5.16B
Div. yield
–
Semiconductor Design Technology
4 wins

Head to Head

11 decided of 12

Synopsys leads on 7 of the 12 questions below (Synopsys 7, Arm Holdings 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSNPSARMVLNLeader
Larger companyMarket capitalisation $90.76B $239.36B $173.28M ARM
Cheaper on earningsLower P/E, profitable companies only 69.7x 229.3x -5.3x SNPS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 31.2x 107.9x — SNPS
Faster revenue growthRevenue growth, trailing twelve months +38.0% +25.1% +7.7% SNPS
More profitableNet margin, trailing twelve months 14.7% 20.2% -45.2% ARM
Better return on capitalReturn on invested capital 1.8% — -34.5% SNPS
Less leveragedLower net debt / EBITDA 2.8x — 3.1x SNPS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -2.1% +30.9% -10.1% ARM
Better 5-year returnAnnualised price return, 5 years +7.3%/yr — -28.8%/yr SNPS
Less volatileAnnualised volatility, 1 year 44.6% 79.0% 102.9% SNPS
Higher overall scoreMean of the five percentile scores vs peers 41/100 62/100 42/100 ARM

Percentile Scorecard

SNPSARMVLN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSNPSARMVLN
Valuation 45 #53 of 95 7 #88 of 95 33 #64 of 95
Growth 50 #47 of 93 88 #12 of 93 15 #79 of 93
Profitability 48 #48 of 91 77 #22 of 91 17 #76 of 91
Financial Health 20 #81 of 101 77 #24 of 101 74 #27 of 101
Shareholder Returns – – 72 #22 of 75
Overall 41 62 42
  • SNPS ranked among 104 companies in Semiconductors
  • ARM ranked among 104 companies in Semiconductors
  • VLN ranked among 104 companies in Semiconductors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSNPSARMVLNSPY
1 month +6.7%-28.0%-14.9% -0.8%
3 months +16.8%-16.1%+0.6% +3.5%
6 months -8.9%+3.5%-0.6% +7.0%
Year to date -3.3%+104.3%+12.7% +12.2%
1 year -2.1%+30.9%-10.1% +13.0%
3 years -0.6%+355.0%-24.2% +86.3%
3 years, per year -0.2%+65.8%-8.8% +23.1%
5 years +42.4%—-81.7% +68.6%
5 years, per year +7.3%—-28.8% +11.0%
10 years +675.8%—— +258.0%
10 years, per year +22.7%—— +13.6%

Risk

MeasureSNPSARMVLNSPY
Volatility, 1Y 44.6%79.0%102.9% 12.7%
Downside volatility, 1Y 42.7%71.2%93.9% 12.7%
Beta vs S&P 500, 1Y 1.673.474.14 1.00
Return / volatility, 1Y -0.050.39-0.10 1.02
Max drawdown, 5Y -42.3%-54.0%-90.1% -25.4%
From 52-week high -15.0%-49.2%-54.7% -1.8%
52-week high $534.56$439.46$3.53 $779.14
52-week low $372.33$104.55$1.11 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSNPSARMVLN
P/E now vs peer median 66.8xmedian 42.1x 227.0xmedian 42.1x -5.1xmedian 42.1x
P/S now vs peer median 9.8xmedian 7.1x 46.0xmedian 7.1x 2.3xmedian 7.1x
EV/EBITDA now vs peer median 40.5xmedian 27.5x 201.3xmedian 27.5x -3.0xmedian 27.5x
P/FCF now vs peer median 31.3xmedian 37.2x 117.8xmedian 37.2x -11.2xmedian 37.2x
P/B now vs peer median 2.8xmedian 4.2x 27.5xmedian 4.2x 1.7xmedian 4.2x
PEG now vs peer median 141.13median 2.23 6.40median 2.23 0.47median 2.23

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSNPSARMVLN
Revenue $8.88B $5.16B $71.70M
Gross profit $6.53B $5.03B $44.29M
Operating income $847.20M $877.00M -$34.09M
Net income $1.30B $1.04B -$32.43M
Free cash flow – $2.01B -$14.77M
R&D $2.81B $2.96B $42.24M
EPS (diluted) $6.77 $0.98 $-0.31
Cash & equivalents $3.61B $3.06B $42.56M
Total debt $10.04B – $343.00K
Shares (diluted) 192.32M 1.07B 103.14M
Enterprise value $87.15B $225.07B -$182.41M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSNPSARMVLN
P/E 66.8x 227.0x -5.1x
P/FCF 31.3x 117.8x -11.2x
P/Operating cash flow – 113.2x -11.8x
P/S 9.8x 46.0x 2.3x
P/B 2.8x 27.5x 1.7x
P/Tangible book 4.4x 28.2x 1.8x
EV/EBITDA 40.5x 201.3x -3.0x
EV/EBIT 110.3x 265.8x -2.4x
EV/Revenue 10.5x 45.2x 1.1x
EV/FCF – 115.8x -5.5x
EV/Operating cash flow – 111.3x -5.9x
PEG (3Y EPS CAGR) 141.13 6.40 0.47

Growth

14 metrics
MetricSNPSARMVLN
Revenue growth (1Y) 38.0% 25.1% 7.7%
Revenue CAGR (3Y) 22.8% 24.7% -8.8%
Gross profit growth (1Y) 28.2% 25.6% 9.3%
Gross profit CAGR (3Y) 18.9% 25.4% -11.0%
Operating income growth (1Y) -23.3% 14.9% 9.1%
Operating income CAGR (3Y) -7.0% 21.6% -10.2%
Net income growth (1Y) -34.9% 49.4% 2.2%
Net income CAGR (3Y) 8.0% 37.2% -12.8%
EPS growth (1Y) -45.2% 48.7% 0.0%
EPS CAGR (3Y) 0.5% 35.5% -10.9%
Operating cash flow growth (1Y) – 105.5% -168.6%
Operating cash flow CAGR (3Y) – 34.7% 7.8%
Free cash flow growth (1Y) – 121.8% -103.3%
Free cash flow CAGR (3Y) – 33.3% 5.9%

Profitability

14 metrics
MetricSNPSARMVLN
Gross margin 73.5% 97.5% 61.8%
EBITDA margin 26.0% 22.5% -37.9%
Operating margin 9.5% 17.0% -47.5%
Pretax margin 16.5% 24.5% -45.1%
Net margin 14.7% 20.2% -45.2%
FCF margin – 39.0% -20.6%
Operating cash flow margin – 40.6% -19.4%
Return on equity 4.2% 16.3% -33.8%
Return on assets 2.7% 12.6% -26.4%
Return on invested capital 1.8% – -34.5%
Return on capital employed 2.0% 9.0% -32.3%
Asset turnover 0.2x 0.5x 0.6x
Cash conversion (OCF / net income) – 2.0x 0.4x
Stock comp / revenue – 22.4% 20.7%

Financial Health

11 metrics
MetricSNPSARMVLN
Debt / assets 21.0% – 0.1%
Debt / equity 0.3x – 0.0x
Net debt / EBITDA 2.8x – 3.1x
Debt / FCF – – 0.0x
Liabilities / assets 34.7% 22.9% 22.1%
Equity / assets 65.3% 77.1% 77.9%
Interest coverage 1.3x – –
Current ratio 1.3x 5.3x 5.2x
Quick ratio 1.0x 4.9x 4.4x
Cash ratio 0.7x 3.2x 4.0x
Altman Z-score 3.76 57.27 1.18

Shareholder Returns

7 metrics
MetricSNPSARMVLN
Dividend yield – – –
Net buyback yield – – 0.9%
Shareholder yield – – 0.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSNPSARMVLN
Forward P/E 31.2xFY2026 107.9xFY2026 –
EPS, next fiscal year $14.56FY2026 $2.07FY2026 $-0.13FY2026
EPS growth, next FY +12.8%FY2026 +16.9%FY2026 –
EPS growth, the year after +21.4% +49.8% –
Revenue, next fiscal year $10.20BFY2026 $5.71BFY2026 $84.56MFY2026
Revenue growth, next FY +44.6%FY2026 +16.0%FY2026 +19.7%FY2026
Revenue growth, the year after +12.8% +38.7% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSNPSARMVLN
Held by institutions 92.3% 9.3% 38.6%
Institutions holding 1,440 955 54
Change in shares held, QoQ +5.6% +12.4% +14.8%
Institutions buying 772 593 38
Institutions selling 493 257 7
Buyers to sellers 1.57 2.31 5.43

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SNPSARMVLN
SNPS 1.00 0.35 0.28
ARM 0.35 1.00 0.44
VLN 0.28 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SNPS, ARM and VLN?

Arm Holdings (ARM) is the largest by market capitalisation: Synopsys (SNPS) $90.76B, Arm Holdings (ARM) $239.36B, Valens Semiconductor (VLN) $173.28M.

Which stock is cheaper, SNPS, ARM and VLN?

Synopsys (SNPS) trades on the lowest price-to-earnings ratio (Synopsys (SNPS) 69.7x, Arm Holdings (ARM) 229.3x, Valens Semiconductor (VLN) -5.3x). On next year's consensus earnings, Synopsys (SNPS) is cheapest (Synopsys (SNPS) 31.2x, Arm Holdings (ARM) 107.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Synopsys (SNPS) grew revenue fastest over the trailing twelve months: Synopsys (SNPS) +38.0%, Arm Holdings (ARM) +25.1%, Valens Semiconductor (VLN) +7.7%.

Which company is more profitable?

Arm Holdings (ARM) has the highest net margin (Synopsys (SNPS) 14.7%, Arm Holdings (ARM) 20.2%, Valens Semiconductor (VLN) -45.2%). On return on invested capital, Synopsys (SNPS) leads (Synopsys (SNPS) 1.8%, Valens Semiconductor (VLN) -34.5%).

Which stock has performed better?

Over the past year Arm Holdings (ARM) returned the most: Synopsys (SNPS) -2.1%, Arm Holdings (ARM) +30.9%, Valens Semiconductor (VLN) -10.1%. Over five years, Synopsys (SNPS) compounded fastest (Synopsys (SNPS) +7.3%/yr, Valens Semiconductor (VLN) -28.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Synopsys (SNPS) has been the steadiest (Synopsys (SNPS) 44.6%, Arm Holdings (ARM) 79.0%, Valens Semiconductor (VLN) 102.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SNPS, ARM and VLN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Synopsys (SNPS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.